AOBiome Therapeutics has reported positive safety results from a Phase Ib/IIa clinical trial of its Ammonia Oxidizing Bacteria (AOB) product candidate for intranasal delivery to treat seasonal allergic rhinitis (SAR).

The trial aims to evaluate the safety and tolerability of the AOB candidate in up to 24 healthy subjects, and preliminary efficacy as a prophylaxis therapy in up to 42 individuals with a history of SAR due to ragweed pollen.

“We believe our intranasal approach has a number of potential applications beyond rhinitis, including migraines.”

The results are included in the first part of the multi-dose, vehicle-controlled trial.

During this part of the study, AOBiome’s candidate demonstrated promising safety and tolerability when delivered intranasally to 24 healthy subjects over a period of two weeks.

The subjects were randomised in a 1:1:1 ratio to provide high dose AOB, low dose, and vehicle, during the study.

Results showed that all adverse effects were mild in severity, and none were considered to be related to the study drug.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

No infectious or inflammatory complications or local/systemic adverse events related to study drug were reported. Additionally, the study did not find any change in nasal patency, anatomy, or architecture of subjects.

AOBiome president and CEO Todd Krueger said: “We are thrilled to announce these latest clinical results, which further underscore the consistently compelling safety findings for our AOB candidate across modalities, including topical and now intranasal delivery.

“We believe our intranasal approach has a number of potential applications beyond rhinitis, including migraines.”

Based on results of the first part of the trial, AOBiome has started the second part of the Phase Ib/IIa trial to examine preliminary efficacy in patients with SAR.